A case of amyloidosis associated with diphenylhydantoin therapy.
Prolonged administration of diphenylhydantoin (DPH) has been implicated as a possible etiologic factor in immunological aberrations and lymphoproliferative disorders. Diphenylhydantoin may account for the increase in susceptibility to lymphoproliferative diseases, as a result of its immunosuppressive effect. We report a case of amyloidosis with monoclonal gammopathy which developed during DPH treatment, without multiple myeloma or lymphoproliferative disorders. The association between DPH and monoclonal gammopathy is very rare, and such a case of amyloidosis associated with DPH has not been reported previously. DPH, however, may have played a role in the development of monoclonal gammopathy, which was the precursor of amyloid protein.
Nomura
S
S
Department of Medicine, Kawasaki Medical School, Okayama, Japan.
Osawa
G
G
Sato
T
T
Ishimatsu
T
T
Shindo
T
T
Hirano
H
H
D000368:Aged; D000686:Amyloidosis / Q000139:chemically induced* / Q000473:pathology; D004834:Epilepsy, Post-Traumatic / Q000188:drug therapy; D005260:Female; D006801:Humans; D006942:Hypergammaglobulinemia / Q000139:chemically induced; D007678:Kidney Glomerulus / Q000648:ultrastructure; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000139:chemically induced; D010672:Phenytoin / Q000009:adverse effects*
D010672:Phenytoin